CurifyLabs, a health technology company developing automated solutions for personalized medicine compounding, has raised $14 million to expand operations in the U.S., strengthen its supply chain, enhance customer support, and accelerate product development.
The funding round was co-led by Sandwater and HealthCap, with participation from Tesi and existing investors, including Lifeline Ventures. U.S. customers and employees also joined the round.
Automating Personalized Medicine
CurifyLabs' Compounding System Solution (CSS) combines proprietary software, GMP-manufactured excipient bases, and 3D printing technology to automate the preparation of personalized medications. The platform enables pharmacies to produce customized doses with greater speed, accuracy, and built-in quality control compared to traditional manual compounding.
The company's technology is already used by pharmacies across Europe and in 21 U.S. states, producing thousands of personalized doses daily.
Supporting Expansion and Innovation
The new capital will support the continued development of the CurifyLabs platform, including the PharmaPrinter Aurum, which prepares personalized medications up to nine times faster than manual methods. The investment will also strengthen supply chain capabilities as the company's pharmacy network continues to grow.